Form 4: Incyte Corp Executive Vice President Barry P. Flannelly Sells $1.15 Million in Common Stock

Barry P. Flannelly, EVP & General Manager US of Incyte Corp, sold 19,164 shares of common stock for approximately $1.15 million on June 12, 2024.

Summary

• On June 12, 2024, Barry P. Flannelly, an Executive Vice President and General Manager US at Incyte Corp, sold 19,164 shares of common stock.
• The sale was executed at a price of $60 per share.
• Following the transaction, Flannelly directly owns 66,377 shares of Incyte Corp common stock, which includes 55,340 shares issuable pursuant to previously reported RSUs and earned performance shares that have not vested.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment, but the market may interpret the sale based on their own analysis.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. It's important to consider the context of the sale, such as the executive's overall holdings and any pre-arranged trading plans.

Comparison to Industry Standards

• Executive compensation and stock ownership structures vary across the pharmaceutical industry.
• Comparing Flannelly's holdings and trading activity to those of executives at similar-sized companies like Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN) could provide a benchmark.
• Analyzing the percentage of shares sold relative to total holdings is a common practice to assess the significance of the transaction.

Stakeholder Impact

• The stock sale could potentially influence investor sentiment, although the impact is likely to be minimal given the size of the transaction relative to the company's overall market capitalization.
• There is no direct impact on employees, customers, suppliers, or creditors.

Key Dates